Empagliflozin: transforming kidney care
Empagliflozin: transforming kidney care In a recent trial, the EMPA-Kidney group, 2023 showed the significant benefits of SGLT2is in CKD patients. Why is this important? Chronic kidney disease (CKD) affects millions globally, posing a risk for kidney failure and heart issues. Enter empagliflozin, initially used for diabetes but now under the spotlight for potentially safeguarding […]
Empagliflozin: transforming kidney care Read More »